FY17
Assets641.00
Net Worth539.92
Total Debt0.49
RevenueAnnualised basis724.96
EBITDAAnnualised basis287.75
PATAnnualised basis241.90
EBITDA Margin (%)39.69
At a glance
Updated 2026-09-02Eris Lifesciences is an IPO with an issue size of ₹1,741.00 crore, proposed for listing on NSE EMERGE.
Issue details
Listing atNSE EMERGE
Issue size₹1,741.00 Cr
Price band—–—
Grey market
GMP page ↗Latest GMPNO GMP
GMP / upper priceNO DATA
Est. listingNO DATA
GMP is unofficial sentiment data, not an exchange price.
Subscription demand
Full bidding ↗NO DATAWaiting for a verified live exchange update.
Company
Financial performance
Year-wise operating scale, profitability and balance-sheet context.Assets357.29₹ Cr · -10.1% vs prior year
Net Worth265.67₹ Cr · -11.2% vs prior year
FY16
Assets397.36
Net Worth299.24
Total Debt[●]
RevenueAnnualised basis597.02
EBITDAAnnualised basis174.92
PATAnnualised basis134.86
EBITDA Margin (%)29.30
FY15
Assets357.29
Net Worth265.67
Total Debt0.50
RevenueAnnualised basis545.56
EBITDAAnnualised basis124.95
PATAnnualised basis89.26
EBITDA Margin (%)22.90
Peer comparison
| Company | EPS | P/E | RoNW | NAV |
|---|---|---|---|---|
| Eris Lifesciences IPO | — | 34.00 x | — | — |
| Symbiotec Pharmalab IPO | — | 61.88 x | — | — |
| Sai Parenteral's IPO | — | 111.58 x | — | — |
| Corona Remedies IPO | — | 35.15 x | — | — |
Registrar & lead managers
Lead managers
- Location
Offer documents
Data is reconciled from multiple public IPO sources. Official exchange filings and offer documents remain the source of truth. Last verified 2026-09-02.
IPO UPDATE ALERTS
Register for IPO Updates →Track Eris Lifesciences without missing an update
Register for subscription, GMP, allotment and listing notifications.